Escherichia coli Infections – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Escherichia coli Infections – Pipeline Review, H2 2017’, provides an overview of the Escherichia coli Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Escherichia coli Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Escherichia coli Infections

The report reviews pipeline therapeutics for Escherichia coli Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Escherichia coli Infections therapeutics and enlists all their major and minor projects

The report assesses Escherichia coli Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Escherichia coli Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Escherichia coli Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Escherichia coli Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adenium Biotech ApS

AstraZeneca Plc

Atterx Biotherapeutics Inc

AvidBiotics Corp

ContraFect Corp

Debiopharm International SA

Emergent BioSolutions Inc

F. Hoffmann-La Roche Ltd

Hsiri Therapeutics LLC

ImmunoClin Corp

Immuron Ltd

Innovation Pharmaceuticals Inc

Johnson & Johnson

Kyorin Pharmaceutical Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

Microbiotix Inc

Nabriva Therapeutics plc

Navigen Inc

Nosopharm SAS

Novabiotics Ltd

Paratek Pharmaceuticals Inc

Phico Therapeutics Ltd

PTC Therapeutics Inc

Recce Ltd

Sealife PHARMA GMBH

Syntiron LLC

Tetraphase Pharmaceuticals Inc

Venus Medicine Research Center

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Escherichia coli Infections - Overview 8

Escherichia coli Infections - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 16

Products under Development by Universities/Institutes 19

Escherichia coli Infections - Therapeutics Assessment 21

Assessment by Target 21

Assessment by Mechanism of Action 24

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Escherichia coli Infections - Companies Involved in Therapeutics Development 31

Adenium Biotech ApS 31

AstraZeneca Plc 31

Atterx Biotherapeutics Inc 31

AvidBiotics Corp 32

ContraFect Corp 32

Debiopharm International SA 33

Emergent BioSolutions Inc 33

F. Hoffmann-La Roche Ltd 34

Hsiri Therapeutics LLC 34

ImmunoClin Corp 35

Immuron Ltd 35

Innovation Pharmaceuticals Inc 35

Johnson & Johnson 36

Kyorin Pharmaceutical Co Ltd 36

Melinta Therapeutics Inc 37

Merck & Co Inc 37

Microbiotix Inc 38

Nabriva Therapeutics plc 38

Navigen Inc 39

Nosopharm SAS 39

Novabiotics Ltd 39

Paratek Pharmaceuticals Inc 40

Phico Therapeutics Ltd 40

PTC Therapeutics Inc 41

Recce Ltd 41

Sealife PHARMA GMBH 42

Syntiron LLC 42

Tetraphase Pharmaceuticals Inc 42

Venus Medicine Research Center 43

Escherichia coli Infections - Drug Profiles 44

A-3APO - Drug Profile 44

AA-139 - Drug Profile 46

AM-8722 - Drug Profile 47

ASN-200 - Drug Profile 48

AvR-2V10 - Drug Profile 49

BC-7634 - Drug Profile 51

BC-9074 - Drug Profile 52

BC-9529 - Drug Profile 53

BC-9563 - Drug Profile 54

BIZ-20131 - Drug Profile 55

BIZ-20132 - Drug Profile 56

BIZ-20133 - Drug Profile 57

CA-824 - Drug Profile 58

CC-1807 - Drug Profile 59

CF-301 - Drug Profile 60

Debio-1454 - Drug Profile 65

delafloxacin meglumine - Drug Profile 66

EBX-004 - Drug Profile 76

Escherichia coli vaccine - Drug Profile 77

Escherichia coli vaccine - Drug Profile 78

ETEC [strain B7A] vaccine - Drug Profile 79

ETEC vaccine - Drug Profile 80

EV-035 - Drug Profile 81

GN Snare - Drug Profile 83

GN-4474 - Drug Profile 84

GYR-12 - Drug Profile 85

HT-07 - Drug Profile 86

infectious disease vaccine - Drug Profile 87

interleukin-22 - Drug Profile 88

JNJ-63871860 - Drug Profile 89

JSM-11 - Drug Profile 91

MBX-2319 - Drug Profile 92

MDN-0057 - Drug Profile 93

mirandamycin - Drug Profile 95

NBTI-5463 - Drug Profile 96

NCL-195 - Drug Profile 97

NOSO-95179 - Drug Profile 98

NP-432 - Drug Profile 99

omadacycline tosylate - Drug Profile 100

Onc-72 - Drug Profile 112

P-100031 - Drug Profile 113

Peptides for Infectious Diseases - Drug Profile 114

Polysaccharides for Bacterial Infections - Drug Profile 115

Proteins for Infectious Diseases - Drug Profile 116

PT-5 - Drug Profile 117

RECCE-327 - Drug Profile 118

Recombinant Protein for Escherichia Coli Infections - Drug Profile 121

RX-04 - Drug Profile 122

RXP-873 - Drug Profile 125

SE-1 - Drug Profile 127

Shigetec - Drug Profile 128

SLP-0901 - Drug Profile 129

SLP-0905 - Drug Profile 130

Small Molecule for Bacterial Infections - Drug Profile 131

Small Molecule for Malaria and Bacterial Infections - Drug Profile 132

Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile 133

Small Molecule to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile 134

Small Molecules for Escherichia coli Infections - Drug Profile 135

Small Molecules for Gram-Negative Bacterial Infections - Drug Profile 136

Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 137

Small Molecules to Inhibit DbpA for Escherichia coli Infections - Drug Profile 138

Small Molecules to Inhibit DNA Gyrase for Gram Negative Bacterial Infections - Drug Profile 139

Small Molecules to Inhibit RecA for Bacterial Infections - Drug Profile 140

SPR-741 - Drug Profile 141

Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 144

Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile 145

Synthetic Peptide to Target Bacterial Cell Membrane for Gram Negative and Gram Positive Bacterial Infections - Drug Profile 146

Synthetic Peptides for Escherichia Coli Infections - Drug Profile 147

Synthetic Peptides for Infectious Disease - Drug Profile 148

tebipenem pivoxil - Drug Profile 149

TN-5 - Drug Profile 150

TP-6076 - Drug Profile 151

VRE-001 - Drug Profile 153

Escherichia coli Infections - Dormant Projects 154

Escherichia coli Infections - Discontinued Products 157

Escherichia coli Infections - Product Development Milestones 158

Featured News & Press Releases 158

Appendix 165

Methodology 165

Coverage 165

Secondary Research 165

Primary Research 165

Expert Panel Validation 165

Contact Us 165

Disclaimer 166

List of Tables

List of Tables

Number of Products under Development for Escherichia coli Infections, H2 2017 14

Number of Products under Development by Companies, H2 2017 16

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18

Number of Products under Development by Universities/Institutes, H2 2017 19

Products under Development by Companies, H2 2017 21

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 22

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 23

Products under Development by Universities/Institutes, H2 2017 24

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 25

Number of Products by Stage and Target, H2 2017 27

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 28

Number of Products by Stage and Mechanism of Action, H2 2017 30

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 31

Number of Products by Stage and Route of Administration, H2 2017 33

Number of Products by Stage and Molecule Type, H2 2017 35

Escherichia coli Infections – Pipeline by Adenium Biotech ApS, H2 2017 36

Escherichia coli Infections – Pipeline by AstraZeneca Plc, H2 2017 36

Escherichia coli Infections – Pipeline by Atterx Biotherapeutics Inc, H2 2017 37

Escherichia coli Infections – Pipeline by AvidBiotics Corp, H2 2017 37

Escherichia coli Infections – Pipeline by ContraFect Corp, H2 2017 38

Escherichia coli Infections – Pipeline by Debiopharm International SA, H2 2017 38

Escherichia coli Infections – Pipeline by Emergent BioSolutions Inc, H2 2017 39

Escherichia coli Infections – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 39

Escherichia coli Infections – Pipeline by Hsiri Therapeutics LLC, H2 2017 39

Escherichia coli Infections – Pipeline by ImmunoClin Corp, H2 2017 40

Escherichia coli Infections – Pipeline by Immuron Ltd, H2 2017 40

Escherichia coli Infections – Pipeline by Innovation Pharmaceuticals Inc, H2 2017 41

Escherichia coli Infections – Pipeline by Johnson & Johnson, H2 2017 41

Escherichia coli Infections – Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017 42

Escherichia coli Infections – Pipeline by Melinta Therapeutics Inc, H2 2017 42

Escherichia coli Infections – Pipeline by Merck & Co Inc, H2 2017 43

Escherichia coli Infections – Pipeline by Microbiotix Inc, H2 2017 43

Escherichia coli Infections – Pipeline by Nabriva Therapeutics plc, H2 2017 44

Escherichia coli Infections – Pipeline by Navigen Inc, H2 2017 44

Escherichia coli Infections – Pipeline by Nosopharm SAS, H2 2017 44

Escherichia coli Infections – Pipeline by Novabiotics Ltd, H2 2017 45

Escherichia coli Infections – Pipeline by Paratek Pharmaceuticals Inc, H2 2017 45

Escherichia coli Infections – Pipeline by Phico Therapeutics Ltd, H2 2017 46

Escherichia coli Infections – Pipeline by PTC Therapeutics Inc, H2 2017 46

Escherichia coli Infections – Pipeline by Recce Ltd, H2 2017 46

Escherichia coli Infections – Pipeline by Sealife PHARMA GMBH, H2 2017 47

Escherichia coli Infections – Pipeline by Syntiron LLC, H2 2017 47

Escherichia coli Infections – Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017 48

Escherichia coli Infections – Pipeline by Venus Medicine Research Center, H2 2017 48

Escherichia coli Infections – Dormant Projects, H2 2017 159

Escherichia coli Infections – Dormant Projects, H2 2017 (Contd..1), H2 2017 160

Escherichia coli Infections – Dormant Projects, H2 2017 (Contd..2), H2 2017 161

Escherichia coli Infections – Discontinued Products, H2 2017 162

List of Figures

List of Figures

Number of Products under Development for Escherichia coli Infections, H2 2017 14

Number of Products under Development by Companies, H2 2017 15

Number of Products under Development by Universities/Institutes, H2 2017 19

Number of Products by Top 10 Targets, H2 2017 26

Number of Products by Stage and Top 10 Targets, H2 2017 26

Number of Products by Top 10 Mechanism of Actions, H2 2017 29

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 29

Number of Products by Top 10 Routes of Administration, H2 2017 32

Number of Products by Stage and Top 10 Routes of Administration, H2 2017 32

Number of Products by Top 10 Molecule Types, H2 2017 34

Number of Products by Stage and Top 10 Molecule Types, H2 2017 34

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports